Lee Ainslie's BIIB Position Overview
Lee Ainslie (via Maverick Capital LTD) currently holds 2,279 shares of Biogen Inc. (BIIB) worth $514,781, representing 0.00% of the portfolio. First purchased in 2016-Q1, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Lee Ainslie has maintained a strategic position in BIIB, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2017, adding 5,620 shares. Largest reduction occurred in Q3 2017, reducing 15,230 shares.
Analysis based on 13F filings available since 2013 Q2
Lee Ainslie's Biogen (BIIB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Biogen (BIIB) Trades by Lee Ainslie
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +2,279 | New Buy | 2,279 | $225.88 |
| Q1 2024 | -1,600 | Sold Out | 0 | $0.00 |
| Q4 2023 | +1,600 | New Buy | 1,600 | $258.77 |
| Q3 2023 | -983 | Sold Out | 0 | $0.00 |
| Q2 2023 | +983 | New Buy | 983 | $284.85 |
| Q4 2021 | -3,112 | Sold Out | 0 | $0.00 |
| Q3 2021 | +3,112 | New Buy | 3,112 | $283.10 |
| Q4 2020 | -1,436 | Sold Out | 0 | $0.00 |
| Q3 2020 | -3,065 | Reduce 68.10% | 1,436 | $283.43 |
| Q2 2020 | +4,501 | New Buy | 4,501 | $267.50 |
| Q4 2019 | -4,919 | Sold Out | 0 | $0.00 |
| Q3 2019 | +4,919 | New Buy | 4,919 | $232.77 |
| Q3 2017 | -15,230 | Sold Out | 0 | $0.00 |
| Q2 2017 | +5,620 | Add 58.48% | 15,230 | $271.37 |
| Q1 2017 | -1,270 | Reduce 11.67% | 9,610 | $273.47 |
| Q4 2016 | +500 | Add 4.82% | 10,880 | $283.55 |
| Q3 2016 | -630 | Reduce 5.72% | 10,380 | $313.01 |
| Q2 2016 | +1,640 | Add 17.50% | 11,010 | $241.78 |
| Q1 2016 | +9,370 | New Buy | 9,370 | $260.30 |
Lee Ainslie's Biogen Investment FAQs
Lee Ainslie first purchased Biogen Inc. (BIIB) in Q1 2016, acquiring 9,370 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie has held Biogen Inc. (BIIB) for 19 quarters since Q1 2016.
Lee Ainslie's largest addition to Biogen Inc. (BIIB) was in Q1 2016, adding 9,370 shares worth $2.44 M.
According to the latest 13F filing for Q3 2026, Lee Ainslie's firm, Maverick Capital LTD, owns 2,279 shares of Biogen Inc. (BIIB), valued at approximately $514,781.
As of the Q3 2026 filing, Biogen Inc. (BIIB) represents approximately 0.00% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.
Lee Ainslie's peak holding in Biogen Inc. (BIIB) was 15,230 shares, as reported at the end of Q2 2017.